TAXIS Pharmaceuticals Chief Scientific Officer Ajit Parhi, PhD, discusses dihydrofolate reductase inhibitors as a novel approach to combat resistant Neisseria gonorrhoeae, a rapidly spreading, deadly, and highly resistant strain of Neisseria gonorrhoeae.
A conversation with Gregory G. Mario and Ajit K. Parhi, Ph.D., TAXIS Pharmaceuticals originally published in Drug Discovery Online.
The prospective bill, the Pasteur Act, is one potential strategy to help in these areas, and incentivize pharmaceutical companies to develop these essential therapies. This article was originally published on contagionlive.com.